Drug used to avoid recurrence of pterygium: March 2011
**Core Concept**
Pterygium is a growth of pinkish or fleshy tissue on the conjunctiva of the eye, often associated with UV exposure. The treatment and prevention of recurrence involve addressing the underlying pathophysiology and modulating the immune response.
**Why the Correct Answer is Right**
To prevent recurrence of pterygium, a topical nonsteroidal anti-inflammatory drug (NSAID) is used to reduce inflammation and inhibit the growth of fibroblasts. This approach targets the underlying pathophysiology of pterygium, which involves an abnormal proliferation of fibroblasts and deposition of collagen. The correct answer is a topical NSAID, specifically **Cyclosporin A** is not a topical NSAID, but a topical NSAID such as **0.5% Ketorolac** is used.
**Why Each Wrong Option is Incorrect**
**Option A:** **Cyclosporin A** is an immunosuppressive agent, not typically used for preventing pterygium recurrence.
**Option B:** **Corticosteroids** may exacerbate pterygium by promoting fibroblast growth and collagen deposition.
**Option C:** **Topical Mitomycin C** is used to prevent scarring after pterygium surgery, not to prevent recurrence.
**Clinical Pearl / High-Yield Fact**
Topical NSAIDs, such as 0.5% Ketorolac, can be used to prevent recurrence of pterygium by reducing inflammation and inhibiting fibroblast growth.
**Correct Answer: B. Corticosteroids may exacerbate pterygium by promoting fibroblast growth and collagen deposition.